Based on Ribo-sep sequencing technology to explore the effect of mRNA and LncRNA editing on the occurrence and development of glioma and its molecular mechanism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044384

Enrollment

Unknown

Registered

2021-03-17

Start date

2021-12-31

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Glioma patients:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients without other serious diseases; 2. No loss or defects in imaging and pathological data; 3. Patients in the glioma group who did not receive radiotherapy or chemotherapy before surgery; 4. Aged 18 to 80 years.

Exclusion criteria

Exclusion criteria: 1. Patients with blood system and immune dysfunction; 2. Two groups of pregnant women during lactation or pregnancy; 3. Patients with abnormal heart, liver, kidney and other malignant tumors; 4. Secondary surgery.

Design outcomes

Primary

Measure	Time frame
Target gene;Ribosome profiling sequencing;long non-coding RNA sequencing;Transcriptome sequencing;	—

Countries

China

Contacts

Public ContactLiu Quan

Liuzhou Workers Hospital

mmnn5200928@163.com+86 13978001893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026